Kangmei Pharmaceutical Valuation

Is 600518 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600518 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 600518's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 600518's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600518?

Key metric: As 600518 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600518. This is calculated by dividing 600518's market cap by their current earnings.
What is 600518's PE Ratio?
PE Ratio	131.8x
Earnings	CN¥255.55m
Market Cap	CN¥32.72b

600518 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.2x
Enterprise Value/EBITDA	59.1x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 600518's PE Ratio compare to its peers?

The above table shows the PE ratio for 600518 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	59.8x
002294 Shenzhen Salubris Pharmaceuticals	59.4x	15.5%	CN¥33.6b
300765 CSPC Innovation Pharmaceutical	77.3x	37.5%	CN¥36.8b
002653 Haisco Pharmaceutical Group	83.1x	35.7%	CN¥36.0b
600079 Humanwell Healthcare (Group)Ltd	19.3x	13.7%	CN¥36.1b
600518 Kangmei Pharmaceutical	131.8x	n/a	CN¥32.7b

Price-To-Earnings vs Peers: 600518 is expensive based on its Price-To-Earnings Ratio (131.8x) compared to the peer average (59.8x).

Price to Earnings Ratio vs Industry

How does 600518's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 600518 is expensive based on its Price-To-Earnings Ratio (131.8x) compared to the CN Pharmaceuticals industry average (29.9x).

Price to Earnings Ratio vs Fair Ratio

What is 600518's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600518 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	131.8x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 600518's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥47.5b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥31.84

-3.9%

14.4%

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.44

-2.0%

18.4%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.3b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥22.24

2.3%

23.4%